Literature DB >> 26598755

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.

Megan C Roberts1, Morris Weinberger2, Stacie B Dusetzina2, Michaela A Dinan2, Katherine E Reeder-Hayes2, Lisa A Carey2, Melissa A Troester2, Stephanie B Wheeler2.   

Abstract

PURPOSE: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake.
METHODS: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer.
RESULTS: A total of 1,468 women with estrogen receptor-positive, human epidermal growth factor receptor-2-negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006).
CONCLUSION: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non-guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26598755      PMCID: PMC4872005          DOI: 10.1200/JCO.2015.63.2489

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Authors:  John Hornberger; Leon E Cosler; Gary H Lyman
Journal:  Am J Manag Care       Date:  2005-05       Impact factor: 2.229

2.  Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Authors:  Juhi Asad; Allyson F Jacobson; Alison Estabrook; Sharon Rosenbaum Smith; Susan K Boolbol; Sheldon M Feldman; Michael P Osborne; Kwadwo Boachie-Adjei; Wendy Twardzik; Paul I Tartter
Journal:  Am J Surg       Date:  2008-10       Impact factor: 2.565

3.  Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.

Authors:  Michaela A Dinan; Xiaojuan Mi; Shelby D Reed; Bradford R Hirsch; Gary H Lyman; Lesley H Curtis
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

4.  Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.

Authors:  Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2015-07-28       Impact factor: 4.872

Review 5.  Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.

Authors:  Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi
Journal:  Contemp Clin Trials       Date:  2012-09-18       Impact factor: 2.226

6.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

7.  Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Authors:  Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

8.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Authors:  Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

9.  Utilization of Oncotype DX in an Inner City Population: Race or Place?

Authors:  Amber A Guth; Susan Fineberg; Kezhen Fei; Rebeca Franco; Nina A Bickell
Journal:  Int J Breast Cancer       Date:  2013-12-18

10.  Oncotype dx results in multiple primary breast cancers.

Authors:  Michael J Toole; Kelley M Kidwell; Catherine Van Poznak
Journal:  Breast Cancer (Auckl)       Date:  2014-01-09
View more
  21 in total

1.  Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Authors:  Carlos H Barcenas; Akshara Raghavendra; Arup K Sinha; Masood Pasha Syed; Limin Hsu; Modesto G Patangan; Mariana Chavez-MacGregor; Yu Shen; Gabriel H Hortobagyi; Vicente Valero; Sharon H Giordano; Naoto T Ueno; Debu Tripathy
Journal:  Cancer       Date:  2017-02-15       Impact factor: 6.860

2.  Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study.

Authors:  Katherine E Reeder-Hayes; Sophie E Mayer; Andrew F Olshan; Stephanie B Wheeler; Lisa A Carey; Chiu-Kit Tse; Mary Elizabeth Bell; Melissa A Troester
Journal:  Cancer       Date:  2019-08-09       Impact factor: 6.860

3.  Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

Authors:  Melissa A Troester; Xuezheng Sun; Emma H Allott; Joseph Geradts; Stephanie M Cohen; Chiu-Kit Tse; Erin L Kirk; Leigh B Thorne; Michelle Mathews; Yan Li; Zhiyuan Hu; Whitney R Robinson; Katherine A Hoadley; Olufunmilayo I Olopade; Katherine E Reeder-Hayes; H Shelton Earp; Andrew F Olshan; Lisa A Carey; Charles M Perou
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

4.  Underutilization of gene expression profiling for early-stage breast cancer in California.

Authors:  Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Helen Chew; Kenneth W Kizer
Journal:  Cancer Causes Control       Date:  2016-04-20       Impact factor: 2.506

5.  Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.

Authors:  Andreana N Holowatyj; Michele L Cote; Julie J Ruterbusch; Kristina Ghanem; Ann G Schwartz; Fawn D Vigneau; David H Gorski; Kristen S Purrington
Journal:  J Clin Oncol       Date:  2018-01-17       Impact factor: 44.544

6.  Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study.

Authors:  Marc A Emerson; Katherine E Reeder-Hayes; Heather J Tipaldos; Mary E Bell; Marina R Sweeney; Lisa A Carey; H Shelton Earp; Andrew F Olshan; Melissa A Troester
Journal:  Curr Breast Cancer Rep       Date:  2020-05-14

7.  The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.

Authors:  Steven J Katz; Timothy P Hofer; Yun Li; Allison W Kurian; Irina Bondarenko; Jeremy M G Taylor; Reshma Jagsi; Kevin C Ward; Ann S Hamilton
Journal:  Breast Cancer Res Treat       Date:  2016-12-23       Impact factor: 4.624

8.  Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.

Authors:  Christopher R Friese; Yun Li; Irina Bondarenko; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Allison W Kurian; Steven J Katz
Journal:  Cancer       Date:  2016-10-24       Impact factor: 6.921

9.  Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.

Authors:  Lu Zhang; Mei-Chin Hsieh; Valentina Petkov; Qingzhao Yu; Yu-Wen Chiu; Xiao-Cheng Wu
Journal:  Breast Cancer Res Treat       Date:  2020-02-14       Impact factor: 4.872

10.  Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.

Authors:  Nicholas Acuna; Jesse J Plascak; Jennifer Tsui; Antoinette M Stroup; Adana A M Llanos
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.